Multiple risk factors have a causative relationship to the etiology of coronary heart disease (CHD). However, it is clear that dyslipidemia plays a central role. The chain of evidence is strongest for elevated levels of total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C). An inverse association has also been demonstrated between levels of high-density lipoprotein cholesterol (HDL-C) and its principal apolipoprotein, A-1, and risk of CHD. Elevated levels of fasting triglyceride (TG) also are a predictor of CHD, but the independent contribution of TG is difficult to prove because of its usual association with reduced levels of HDL-C; elevated levels of small, dense, highly-atherogenic LDL particles; and the metabolic syndrome. Elevated fasting levels of non—HDL-C (TC — LDL-C) and apolipoprotein B also are strongly predictive of the risk of CHD. Therapeutic lifestyle changes are important adjuncts to pharmacologic management of dyslipidemia. The purpose of this article is to review these contributions with an emphasis on dietary habits (particularly lipid intake), weight management, and aerobic exercise.
AHA Statistical Update.Heart Disease and Stroke Statistics-2008 Update. Dallas, TX: American Heart Association; 2008.
2.
Brown MS, Goldstein JLFamilial hypercholesterolemia defective binding of lipoproteins to cultured fibroblatis with impaired regulation of 3-hydroxy-3 methylglutanyl coenzyme A reductase activity. Proc Natl Acad Sci U S A. 1974;71:788-792.
3.
Aschoff LLEin Beitrag Zur Myelinfrage. Verh Disch Path Ges. 1907;10:166-160.
4.
Kao VC, Wissler RWA study of the immunohistochemical localization of serum lipoproteins and other plasma protein in human atherscherotic lesions. Exp Mol Pathol. 1965;4:465-470.
5.
Committee on Diet and Health, Food and Nutrition Board, Commission on Life Science, National Research Council.Fats and other lipids. In: Diet and Health Implications for Reducing Chronic Disease Risk. Washington DC: National Academy Press; 1989:154-288.
6.
Manalo-Estrella P., Cox GE, Taylor CBAtherosclerosis in rhesus monkeys VII. Mechanisms of hypercholesterolemia: hepatic cholesterolgenesis and the hypercholesterolemic threshold of dietary cholesterol. Arch Pathol. 1963;76:413-423.
7.
Keys A.Coronary heart disease-the global picture. Atherosclerosis . 1975;22:149-152.
8.
Keys A, ed. Coronary Heart Disease in Seven Countries. Monograph No. 29. Dallas, TX; American Heart Association; 1970.
9.
Kannel WB, McGee D., Gordon T.A general cardiovascular risk profile: the Framington Study. Am J Cardiol. 1976;38:46-51.
10.
The Pooling Project Research Group.Relationship of Blood Pressure, Serum Cholesterol, Smoking Habits, Relative Weight and ECG Abnormalities to Incidence of Major Coronary Events. Final Report of the Pooling Project. American Heart Association Monograph Number 60. Dallas, TX: American Heart Association; 1978.
11.
Stamler J., Wentworth D., Neston JDIs the relationship between serum cholesterol continuous and graded? Findings from the Multiple Risk Factor Intervention Trial (MRFIT)JAMA. 1986;256:2823-2828.
12.
Mudd JO, Borlaug BA, Johnson PV, et al. Beyond low-density lipoprotein cholesterol. J Am Coll Cardiol. 2007;50:1735-1741.
13.
Batter PJ, Ballantyne CM, Carhona R., et al. APO B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-one person/thirty-country panel. J Intern Med. 2006;259:247-258.
14.
Bergland L. , Anuurad E.Role of apoprotein (a) in cardiovascular disease: current and future prospective. Circulation. 2008;52:132-134.
15.
Gotto AM Jr.Contemporary Diagnosis and Management of Lipid Disorders. 3rd ed. Newton, PA: Handbooks in Health Care; 2004.
16.
Buchwald H. , Varco RI, Matts JP, et al. Effect of partial ilial bypass on mortality and morbidity from coronary artery disease in patients with hypercholesterolemia . N Engl J Med. 1990;323:153-162.
17.
LaRosa JC, He J., Vuppututi S.Effects of statins on risk of coronary heart disease: a meta-analysis of randomized trials. JAMA. 1999;282:23430-2346.
18.
Ray KK, Cannon CPThe potential relevance of the multiple lipid-independent (pleiotropic) effects of statins in management of the acute coronary syndrome. J Am Coll Cardiol. 2005;46:1425-1433.
19.
Reilly SD, Litovsky SH, Seinkamp MP, Caulfield JBStatins improve human coronary arteriosclerotic plaque morphology . Tex Heart Inst J. 2008;35:99-103.
20.
Libby P.Atherosclerosis: the new view. Sci Am. 2002 ;2886:47-55.
21.
Steinberg D.Low density lipoprotein oxidation and its pathologic significance. J Biol Chem. 1997;272:20963-20966.
22.
Barr DP, Ross EM, Eder HAProtein-lipid relationships in human plasma. Am J Med. 1951;11:480-493.
23.
Gordon DJ, Probstfield JL, Garrison RJ, et al. High-density lipoprotein cholesterol and cardiovascular disease: four prospectiveAmerican studies. Circulation. 1989;79:8-19.
24.
Francis MC, Frohlich JJCoronary artery disease in patients at low risk: apolipoprotein A-I as an independent risk factor. Atherosclerosis. 2001;155:167-170.
25.
Rubins HR, Robins SJ, Collins D., et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veteran's Affairs High-Density Lipoprotein Intervention Trial Study Group. N Engl J Med. 1999;34:410-418.
26.
Assmann G., Noter JR, Atheroprotective effects of high-density lipoprotein. Annu Rev Med. 2003;54:321-341.
27.
Dansky HM, Fischer EAHigh-density lipoprotein and plaque regression: the good cholesterol gets even better. Circulation. 1999;100:1767-1763.
28.
Baymes JW, Dominiczac MH, eds. Lipids and lipoproteins. In: Medical Biochemistry. 2nd ed. Philadelphia, PA: Elsevier Mosby; 2005:225-243.
29.
Chiesa G., Sirtori CRApolipoprotein A-1 Milano: current perspectives. Curr Opin Lipidol. 2003;14:159-163.
30.
Zarraga IGE , Schman ERImpact of dietary patterns and intervention on cardiovascular health. Circulation. 2006 ;114:961-973.
31.
Nissen SE, Tardif JC, Nichols SJ, et al. Effect of torcetrapib on the progression of coronary atherosclerosis . N Engl J Med. 2007;156:1014-1015.
32.
Kastelein JJ , van Leuven SI, Burgess L., et al. Effects of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med. 2007;256:1620-1630.
33.
Van der Steeg WA, Holme I., Boekholdt SM, et al. High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-1: significance for cardiovascular risk. The IDEAL and EPIC-Norfolk Studies J Am Coll Cardiol. 2008;51:634-640.
34.
Genest J.The yin and yang of high-density lipoprotein cholesterol. J Am Coll Cardiol. 2008;51:643-646.
35.
Tanaka A., Al M., Kobayashi Y., et al. Metabolism of triglyceride-rich lipoprotein and their role in atherogenesis. Ann N Y Acad Sci. 2001;947:207-213.
36.
Sarwar N., Danesh J., Elrlksdotir G., et al. Triglyceride and the risk of coronary heart disease; 10,158 incident cases among 262,525 participants in 29 Western prospective studies . Circulation. 2007;15:450-458.
37.
Hokanson JE , Austin MAPlasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies . J Cardiovasc Risk. 1996;5:213-219.
38.
Miller M., Cannon C., Murphy SA, et al; for the PROVE IT-TIMI 22 Investigators.Impact of triglyceride levels beyond low density lipoprotein cholesterol after an acute coronary syndrome in the PROVE IT-TIMI trial. J Am Coll Cardiol. 2008;51:724-730.
39.
Adult Treatment Panel III.Executive summary of the third report of the National Cholesterol Education Program (NCEP): expert panel on the detection, evaluation, and treatment of high blood cholesterol in adults. JAMA. 2001 ;285:2486-2497.
40.
Pischon T., Girman CT, Sacks FM, et al. Non-high density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men. Circulation . 2005;112:3375-3383.
41.
Kastelein JJ , van der Steeg WA, Holme I., et al. Lipids, apolipoproteins, and their ratios in relationship to cardiovascular events with statin treatment . Circulation. 2008;117:3002-3009.
42.
Snidermann ADApoliprotein B versus non-high-density lipoprotein cholesterol and the winner is. Circulation. 2005;112:3366-3373.
43.
Grundy SM, Cleeman JL, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Panel for Adult Treatment Panel III Guidelines. Circulation. 2004;110:2142-2146.
44.
Friedewald WT, Levy R., Fredrickson DSEstimation of the concentration of low density lipoprotein cholesterol in plasma without the use of the preparatory ultracentrifuge . Clin Chem. 1972;18:499-502.
45.
D'Agostino RB, Ramachandran SV, Pencina ML, et al. General cardiovascular risk profile for use in primary care. The Framingham Heart Study. Circulation . 2008;117:743-753.
46.
Bettridge DJ , Morrell JMClinician's Guide to Lipids and Coronary Heart Disease. 2nd ed. London , UK: Arnold; 2003.
47.
Duffy D., Rader DJEmerging therapies targeting high-density lipoprotein metabolism and reverse cholesterol transport. Circulation. 2005;113:1140-1150.
48.
Trichopoulous A., Costaco T., Bamia C., Trichopoulous D.Mediterranean diet and survival in a Greek population. N Engl J Med. 2003;348:2599-2608.
49.
deLorgeri M. , Renaud S., Manelle M., et al. Mediterranean alpha linoleic acid rich diet in secondary prevention of coronary heart disease. Lancet. 1994;343:1454-1459.
50.
Keys A., Parling RWSerum cholesterol response to dietary lipids. Am J Clin Nutr . 1966;19:171-181.
51.
Jones PJH . Regulation of cholesterol biosynthesis by diet in humans. Am J Clin Nutr. 1997;66:438-446.
52.
Fernandez JL , West KLMechanisms by which dietary fatty acids modulate plasma lipids. J Nutr. 2005;135:2075-2078.
53.
Breslow JLn-3 fatty acids and cardiovascular disease. Am J Clin Nutr . 2006;83(suppl):1477S-1482S.
54.
Artherburn L., Hall EB, Oken H.Distribution, interconversion, and dose response of n-3 fatty acids. Am J Clin Nutr. 2006;83(suppl):1467S-1476S.
55.
Bang HO, Dyerberg J.Lipid metabolism and ischemic heart disease in Greenland Eskimos. In: Draper HH, ed. Advances in Nutrition Research. New York, NY: Plenum;1980:1-22.
56.
He K., Song Y., Daviglus ML, et al. Accumulated evidence on fish consumption and coronary heart disease: a meta-analysis of cohort studies. Circulation. 2004;109:2705-2711.
57.
Von Schacky C. n-3 fatty acids and the prevention of coronary atherosclerosis. Am J Clin Nutr. 200;71(suppl):224S-227S.
58.
Harris WSn-3 fatty acids and lipoproteins: comparison of results from human and animal studies. Lipids. 1996;31:243-252.
59.
Holub BUClinical nutrition: 4. Omega-3 fatty acids in cardiovascular care . CMAJ. 2002;116:608-615.
60.
Davidson MH , Stein EA, Bay HEEfficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled trial. Clin Ther. 2007;29:1354-1367.
61.
Gordner CD, Kraemer HCMonounsaturated versus polyunsaturated fat and serum lipids: a meta-analysis . Arteroscler Thromb Vasc Biol. 1995;15:1917-1927.
62.
Graf PA, Lemke S., Di Rienzo M.Reducing the trans-fatty acids content of foods Regulatory and food industry approaches. Nutr Today. 1008;43(2):46-51.
63.
Stender S., Dyerberg J., Hølmer G., Oveson L., Sandström B.The influence of trans fatty acids on health: a report from the Danish Nutritional Council. Clin Sci (Lond). 1995;88(4):375-392.
64.
Brown L., Rosner B., Willett WW, Sachs FMCholesterol-lowering effects of dietary fiber: a meta-analysis. Am J Clin Nutr. 1999;69:30-42.
65.
Pereira MA, O'Reilly E., Augustsson K., et al. Dietary fiber and risk of coronary heart disease: a pooled analysis of cohort studies. Arch Intern Med. 2004;164:370-376.
66.
Jacobs DR Jr, Gallaher DDWhole grain intake and cardiovascular disease: a review. Curr Atheroscler Rep. 2004;6:415-423.
67.
Dauchet L., Amouyel P., Hercberg S., Dallonguille J.Fruits and vegetables consumption and risk of coronary heart disease: a meta-analysis of cohort studies. J Nutr. 2006;136:2588-2593.
68.
Law M.Plant sterol and stanol margarine and health. BMJ . 2000;320:861-864.
69.
Miettingen T., Puska P., Gylling H. et al. Reduction of serum cholesterol with sitosterolester margarine in a mildly hypercholesterolemic population. N Engl J Med. 1995;333:1308-1312.
70.
Fletcher B. , Berra K., Braun L., et al. Managing abnormal blood lipids: a collaborated approach. Circulation. 2005;112:3184-3209.
71.
Hooper L., Ness AR, Smith GDMeta-analysis of effect of high versus low vitamin E intake on cardiovascular mortality for observational and interventional studies. Lancet . 2001;357:1705-1706.
72.
Law M., Wald N.The relative risk of CHD death according to alcohol consumption in the five largest cohort studies. Br Med J. 1999;318:1471-1480.
Fraser GE, Sabate J., Beeson WL, et al. A possible protective effect of nut consumption on risk of coronary heart disease. The Adventurist Health Study. Arch Intern Med . 1992;152:1416-1424.
75.
Kokubo Y., Iso H., Ishihar J., et al. Association of dietary intake of soy, beans and isoflavones with risk of cerebral and myocardial infarction in Japanese populations. The Japan Public Health Center-Based (JPPHC) Study Cohort 1. Circulation. 2006;116:2553-2562.
76.
Becker DJ, Gordon RY, Morris RD, et al. Simvastatin vs. therapeutic lifestyle changes and supplements: Randomized primary prevention trial. Mayo Clin Proc. 2008;83:758-765.
77.
National Institute of Health.Clinical Guidelines on the Identification, Evaluation and Treatment of Overweight and Obesity in Adults. The Evidence Report. NIH Publication No. 98-408. Bethesda, MD; National Institutes of Health ; 1998.
78.
Klein S., Burke LE, Bray GA, et al. Clinical implications of obesity with specific focus on cardiovascular disease. A statement for professionals from the American Heart Association Council on Nutrition, Physical Activity and Metabolism. Circulation . 2004;110:2952-2967.
79.
Jakicic JM, Clark K., Coleman E., et al. American College of Sports Medicine.Position Stand. Appropriate intervention strategies for weight loss and prevention of weight regain for adults. Med Sci Sports Exerc. 2001;12:2145-2156.
80.
Danttilo AM , Kris-Etherton PMEffects of weight reduction on blood lipids and lipoproteins: a meta-analysis. Am J Clin Nutr. 1992;56:320-328.
81.
Nordmann AL , Nordmann A., Briel M., et al. Effects of a low-carbohydrate vs. low fat diet on weight loss and cardiovascular risk factors: a meta-analysis of randomized controlled trials. Arch Intern Med. 2006;166:285-293.
82.
Shai I., Schwarzfuchs D., Henkin Y., et al. Weight loss with a low-carbohydrate, Mediterranean or low fat diet. N Engl J Med. 2008;359:229-241.
83.
Klem ML, Wing RA, McGuire MT, et al. A descriptive study of individuals successful at long term maintenance of substantial weight loss. Am J Clin Nutr. 1997;66: 239-246.
84.
Saris WH, Blair SN, van Baak MM, et al. How much physical activity is enough to prevent unhealthy weight gain? Outcome of the IASO 1st Stock Conference and Consensus Statement. Obes Rev. 2003;4: 101-114.
Clark AM, Harling L., Vandermeer B., Mcallister FAMeta-analysis: secondary prevention programs for patients with coronary heart disease. Ann Intern Med. 2005;143:659-672.
87.
Leon AS, Bronas UGPathophysiology of coronary heart disease and biological mechanisms for the cardioprotective effects of regular exercise. Am J Lifestyle Med. In press.
88.
Leon AS, Franklin BA, Costa F., et al. Cardiac rehabilitation and secondary prevention of coronary heart disease. An American Heart Association Scientific Statement. Circulation. 2005;111:369-376.
89.
Kodama S., Tanaka S., Saito K., et al. Effects of aerobic exercise training on serum levels of high-density lipoprotein cholesterol: a meta-analysis. Arch Intern Med . 2007;167:999-1008.
90.
Durstine SL, Grandjean PW, Cox CA, Thompson PDLipids, lipoproteins, and exerciseJ Cardiopulm Rehab . 2002;22: 389-398.
91.
Leon AS, Sanchez OAResponse of blood lipids to exercise training alone or combined with dietary intervention. Med Sci Sports Exerc. 2001;33(suppl):S502-S515.
92.
Leon AS, Rice R., Mandel S., et al. Blood lipid response to 20 weeks of supervised exercise in a large biracial population: the HERITAGE Family Study. Metabolism . 2001;S513-S520.
93.
Leon AS, Gaskill SE, Rice T., et al. Variability in the response of HDL cholesterol to exercise training in the HERITAGE Family Study. Int J Sports Med. 2001;22:1-9.
94.
Rice T., Deprés J.-P, Pérusse L., et al. Familial aggregation of blood lipid response to exercise training in the Health Risk Factors, Exercise Training, and Genetics (HERITAGE) Family Study. Circulation. 2002;105:1904-1908.
95.
Stefanick M.Physical activity for preventing and treating obesity-related dyslipoproteinemias. Med Sci Sports Exerc . 199;31(suppl):S609-S618.
96.
Santiago MC , Leon AS, Serfass RCFailure of 40 weeks of brisk walking to alter blood lipids in normolipemic women. Can J Appl Phys . 1995;20:417-428.
97.
Sopko G., Leon AS, Jacobs DR Jr, et al. The effect of exercise and weight loss on plasma lipids in obese young men. Metabolism. 1988;34:227-236.
98.
Wood PD, Haskell WL, Blair SN, et al. Increased exercise level and plasma lipoprotein concentration: a one year randomized, controlled study in sedentary middle-aged men. Metabolism. 1983;32:31-39.
99.
Ockene IS, Miller NHCigarette smoking, cardiovascular disease and stroke: a statement for healthcare professionals from the American Heart Association Task Force on Risk Reduction . Circulation. 1997;96: 3243-3247.
100.
Kannell WBUpdate on the role of cigarette smoking in coronary artery disease . Am Heart J. 1981;101:319-328.
101.
Goldbourt J. , Medalie JHCharacteristics of smokers, nonsmokers, and exsmokers among 10,000 adult males in Israel II. Physiologic biochemical, and genetic characteristics. Am J Epidemiol. 1997;105: 75-84.
102.
Craig W., Palomaki G., Haddow J.Cigarette smoking and serum lipids and lipoprotein concentrations: analysis of published data. BMJ. 1989;298:784-788.
103.
Gottto A., Powenall H.Manual of Lipid Disorders: Reducing the Risk of Coronary Heart Disease . 2nd ed. Baltimore, MD: Williams and Williams; 1999:179.
104.
Harats D., Ben-Nain M., Dabach Y., et al. Cigarette smoke renders LDL susceptible to peroxidative modification and enhanced metabolism by macrophages. Artherosclerosis. 1989;79:245-252.
105.
Chiuve SE, McCullough ML, Sacks FM, Rimm EBHealthy lifestyle factors in the prevention of coronary heart disease among men: benefits among users and nonusers of lipid-lowering and antihypertensive medication. Circulation. 2000;114:160-167.
106.
Iestra JA, Kromhout D., Van der Schouw YT, et al. Effect size of lifestyle and dietary changes on all-cause mortality in coronary artery disease patients: a systematic review. Circulation. 2005;112:924-939.
107.
Heidemamn C., Schulze MB, Franco OH, et al. Dietary patterns and risk of mortality from cardiovascular disease, cancer, and all-causes mortality in a prospective cohort of women. Circulation. 2008;118:230-237.
108.
Appel LJDietary patterns and longevity: expanding the blue zones. Circulation. 2008;118:214-215.
109.
Position of the American Dietetic Association and Dieticians of Canada. Vegetarian diets. J Am Diet Assoc. 2003;103:748-765.
110.
Sabate J.The contribution of vegetarian diets to health and disease: a paradigm shift?Am J Clin Nutr. 2003;78(suppl):502S-507S.
111.
Mitrow FN, Kipnis V., Thiebaut ACM, et al. Mediterranean dietary patterns and prediction of all-cause mortality in a US populations: results from the NIH-AARP Diet and Health Study. Arch Intern Med. 2004;167:2461-2468.
112.
Knoops KTB , de Groot Lcpgm, Kromhout D., et al. Mediterranean diet, lifestyle factors, and 10-year mortality in elderly European men and women. The HALE Project . JAMA. 2004;292:1433-1439.
113.
Fung TT, Chiuve SE, McCullough ML, et al. Adherence to DASH-style diet and risk of coronary heart disease and stroke in women. Arch Intern Med. 2008 ;168:713-720.
114.
Sacks FM, Appel LJ, Moore TJ, et al. A dietary approach to prevent hypertension: a review of the Dietary Approach to Stop Hypertension (DASH) Study. Clin Cardiol . 1999;22(suppl):III-6-III-10.
115.
Lichenstein AH, Appel LJ, Brands M., et al. Diet and lifestyle recommendations revision 2006: a scientific statement from the Nutrition Committee . Circulation. 2006;114:82-96.
116.
Yu-Poth S., Zhao G., Etherton T., et al. Effects of the National Cholesterol Education Program's Step 1 and Step 2 dietary intervention programs on cardiovascular risk factors: a meta-analysis. Am J Clin Nutr. 1999;69:632-646.
117.
US Department of Agriculture and US Department of Health and Human Services Dietary Guidelines for Americans 2005. www.healtierus.gov/dietaryguidelines.
118.
US Department of Health and Human Services.Your Guide to Lowering Cholesterol With TLC (Therapeutic Lifestyle Changes). NIH Publication No. 06-523S. Bethesda, MD: National Institutes of Health; 2009.
119.
Varady KA, Jones PJH.Combination diet and exercise interventions for the treatment of dyslipidemia: an effective preliminary strategy to lower cholesterol levels? J Nutr. 2005;135:1829-1835.
